

April 29, 2025

To,
Mr. Amit Shinde
Chief Manager
Surveillance Department,
The National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051.

Scrip Name: GLENMARK

Ref: Your email dated April 28, 2025

Dear Sir,

Sub: Clarification /Confirmation on news item appearing in “Media/Publication”

We refer to your e-mail dated April 28, 2025 seeking clarification on the recent news item which appeared in the “www.freepressjournal.in” dated April 28, 2025 captioned “CDSCO Flags 70 Drug Batches, Including Telma 40 And Eye Ointments, For Failing Quality Standards In March 2025 Tests”

At the outset, we wish to inform you that products referred to in the said News Article are spurious products which have not been manufactured by Glenmark Pharmaceuticals Limited or any of its affiliates. As you will notice in the News Article also we have denied manufacturing the same and have clarified to FPJ that the same was manufactured / sold by counterfeiters. Regulatory Authorities (i.e. CDSCO as well as Department of Health & Family Welfare, Government of West Bengal) have issued various notifications in this regard wherein they have notified that the said products in question are spurious.

Since this is a counterfeit issue and the products in question are not manufactured by Glenmark Pharmaceuticals Limited this was not intimated to the exchanges. We have been proactive in informing the Exchange about the events of the Company and we will continue to do so.

As an organization we have (and continue to do so) taken numerous steps to counter the menace of spurious / counterfeit products including changes in packaging and strengthening our product supply chain, creating awareness etc. to ensure the authenticity of its drugs.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer